Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
NCT02061865
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Wet Age-related Macular Degeneration (AMD)
Interventions
DRUG:
REGN2176-3
Sponsor
Regeneron Pharmaceuticals